13. In the treatment of bladder cancers, which of the following statements are true?except
A Non-muscle invasive (superficial) tumours are treated by endoscopic resection and a single dose of mitomycin instillation.
B Grade 3 superficial disease is best managed by BCG immunotherapy.
C External beam radiotherapy should be the first-line treatment in muscleinvasive disease.
D When the cancer has invaded muscle (pT2 and pT3) radical cystectomy and lymphadenectomy is the treatment of choice.
E Neoadjuvant cisplatin-based chemotherapy improves survival in muscle-invasive tumours.
A Non-muscle invasive (superficial) tumours are treated by endoscopic resection and a single dose of mitomycin instillation.
B Grade 3 superficial disease is best managed by BCG immunotherapy.
C External beam radiotherapy should be the first-line treatment in muscleinvasive disease.
D When the cancer has invaded muscle (pT2 and pT3) radical cystectomy and lymphadenectomy is the treatment of choice.
E Neoadjuvant cisplatin-based chemotherapy improves survival in muscle-invasive tumours.
1. The following statements are true except:
A The prostate is anatomically divided into a peripheral zone, a central zone and a transitional zone.
B The glands of the peripheral zone are lined by transitional epithelium.
C Benign prostatic hypertrophy occurs in the transitional zone.
D Most carcinomas arise in the peripheral zone.
E Denonvilliers’ fascia separates the prostate from the rectum.
A The prostate is anatomically divided into a peripheral zone, a central zone and a transitional zone.
B The glands of the peripheral zone are lined by transitional epithelium.
C Benign prostatic hypertrophy occurs in the transitional zone.
D Most carcinomas arise in the peripheral zone.
E Denonvilliers’ fascia separates the prostate from the rectum.
Which of the following statements are true?except
A Luteinising hormone (LH) from the anterior pituitary controls the secretion of testosterone.
B Leydig cells from the testes secrete 90% of the testosterone.
C The enzyme 5α-reductase type II is found in high concentration in the prostate.
D 5α-reductase converts testosterone into 1.5-dihydrotestosterone (DHT).
E Prostate-specific antigen (PSA) is both specific and sensitive in the diagnosis of prostate cancer.
A Luteinising hormone (LH) from the anterior pituitary controls the secretion of testosterone.
B Leydig cells from the testes secrete 90% of the testosterone.
C The enzyme 5α-reductase type II is found in high concentration in the prostate.
D 5α-reductase converts testosterone into 1.5-dihydrotestosterone (DHT).
E Prostate-specific antigen (PSA) is both specific and sensitive in the diagnosis of prostate cancer.
Study room 808
Which of the following statements are true?except A Luteinising hormone (LH) from the anterior pituitary controls the secretion of testosterone. B Leydig cells from the testes secrete 90% of the testosterone. C The enzyme 5α-reductase type II is found in…
بروستات حيبين اكو خلل ميبين هو كانسر لو hyperplasia لو enlargement
4. In urodynamic studies, which of the following statements are true?except
A A voided volume >200 mL with a peak flow rate >15 mL/s is normal.
B A voiding pressure of <60 cm H2 O is normal.
C Increase in voiding pressures with a low flow rate is diagnostic of BOO.
D In patients with a residual volume of 250 mL or more, bilateral hydronephrosis will result.
E Urodynamically proven BOO only occurs from BPH.
A A voided volume >200 mL with a peak flow rate >15 mL/s is normal.
B A voiding pressure of <60 cm H2 O is normal.
C Increase in voiding pressures with a low flow rate is diagnostic of BOO.
D In patients with a residual volume of 250 mL or more, bilateral hydronephrosis will result.
E Urodynamically proven BOO only occurs from BPH.
Management of BPH causing BOO
6. Which of the following statements are true?except
A All patients with acute retention ultimately require prostatectomy.
B Chronic retention accounts for 15% of prostatectomies.
C Severe symptoms account for 60% of prostatectomies.
D Drug therapy is with α-blockers and/or 5α-reductase inhibitor.
E A low maximum flow rate of <10 mL/s and a residual volume of 100–250 mL are indications for surgery.
6. Which of the following statements are true?except
A All patients with acute retention ultimately require prostatectomy.
B Chronic retention accounts for 15% of prostatectomies.
C Severe symptoms account for 60% of prostatectomies.
D Drug therapy is with α-blockers and/or 5α-reductase inhibitor.
E A low maximum flow rate of <10 mL/s and a residual volume of 100–250 mL are indications for surgery.
Management of BPH causing BOO
6. Which of the following statements are true?except
A All patients with acute retention ultimately require prostatectomy.
B Chronic retention accounts for 15% of prostatectomies.
C Severe symptoms account for 60% of prostatectomies.
D Drug therapy is with α-blockers and/or 5α-reductase inhibitor.
E A low maximum flow rate of <10 mL/s and a residual volume of 100–250 mL are indications for surgery.
6. Which of the following statements are true?except
A All patients with acute retention ultimately require prostatectomy.
B Chronic retention accounts for 15% of prostatectomies.
C Severe symptoms account for 60% of prostatectomies.
D Drug therapy is with α-blockers and/or 5α-reductase inhibitor.
E A low maximum flow rate of <10 mL/s and a residual volume of 100–250 mL are indications for surgery.